바이오노트, 1분기 영업익 63억…전년比 35.16% 증가

BioNote's strong Q1 performance highlights a successful transition and growth phase in the post-pandemic In-vitro Diagnostics (IVD) market. The exceptional surge in net profit provides significant capital for potential reinvestment in R&D and global expansion, signaling a positive outlook for the bio-diagnostic sector.